6CM
ITOS

683 Capital Management’s iTeos Therapeutics ITOS Stock Holding History

683 Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,750,000
Closed -$10.4M – 144
2025
Q1 		$10.4M Buy
1,750,000
+831,883
+91% +$6.11M 0.72% 39
2024
Q4 		$7.05M Sell
918,117
-652,171
-42% -$5.6M 0.44% 54
2024
Q3 		$16M Buy
1,570,288
+455,288
+41% +$6.95M 1.22% 26
2024
Q2 		$16.5M Buy
1,115,000
+400,000
+56% +$5.73M 1.25% 22
2024
Q1 		$9.75M Hold
715,000
– – 0.71% 43
2023
Q4 		$7.83M Sell
715,000
-95,000
-12% -$942K 0.64% 52
2023
Q3 		$8.87M Buy
810,000
+225,000
+38% +$2.88M 0.69% 51
2023
Q2 		$7.75M Buy
585,000
+105,000
+22% +$1.5M 0.56% 50
2023
Q1 		$6.53M Buy
480,000
+330,000
+220% +$5.91M 0.49% 61
2022
Q4 		$2.93M Buy
+150,000
New +$2.93M 0.25% 89
2021
Q4 		– Sell
-200,413
Closed -$5.41M – 353
2021
Q3 		$5.41M Buy
+200,413
New +$5.24M 0.21% 80

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

683 Capital Management's ITOS Position: Q2 2025 in Review

683 Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 1,750,000 shares — an estimated $10.4M sold.

683 Capital Management first reported a position in ITOS in Q3 2021 and held it in 11 quarters. The position peaked at $16.5M in Q2 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • 683 Capital Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • 683 Capital Management sold 1,750,000 iTeos Therapeutics shares in Q2 2025, an estimated $10.4M.
  • 683 Capital Management first reported a position in iTeos Therapeutics in Q3 2021 and held it in 11 quarters.
  • 683 Capital Management's iTeos Therapeutics position peaked at $16.5M in Q2 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on 683 Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.